Status:
UNKNOWN
Rheumatologic Adverse Events and Cancer Immunotherapy
Lead Sponsor:
Poitiers University Hospital
Conditions:
Oncology
Autoimmunity
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In this study, every patient with cancer who is going to be treated by immunotherapy will fill in a form. In this form, we try to determine if he presents rheumatologic complications of his immunother...
Eligibility Criteria
Inclusion
- Patient with cancer needed to be treated by immunotherapy
Exclusion
- Patient already treated by immunotherapy
Key Trial Info
Start Date :
May 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 7 2022
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04791150
Start Date
May 7 2021
End Date
November 7 2022
Last Update
May 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
C.H.U de Poitiers
Poitiers, France, 86000